Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

Research output: Contribution to journalArticle


The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.


Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology


  • Gene Rearrangement B-Lymphocyte : genetics, Human, Immunophenotyping, Lymphoma B-Cell : drug therapy : genetics, Leucovorin : therapeutic use, Lactate Dehydrogenase : metabolism, Lymphoma Large-Cell Diffuse : drug therapy : genetics, Male, Methotrexate : therapeutic use, Middle Age, Neoplasm Staging, Prednisone : therapeutic use, Prognosis, Proto-Oncogene Proteins : genetics, Support Non-U.S. Gov't, Vincristine : therapeutic use, Transcription Factors : genetics, Doxorubicin : therapeutic use, DNA-Binding Proteins : genetics, DNA Neoplasm : analysis : metabolism, Cyclophosphamide : therapeutic use, Blotting Southern, Bleomycin : therapeutic use, Antineoplastic Combined Chemotherapy Protocols : therapeutic use, Aged, Adolescence, Adult
Original languageEnglish
Pages (from-to)161-165
JournalInternational Journal of Oncology
Issue number1
Publication statusPublished - 2002
Publication categoryResearch

Bibliographic note

The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000), Division of Clinical Genetics (013022003), Oncology, MV (013035000)